Epigenetic Precision Medicine: Selective Deacetylase Inhibitor Development & Isoform-Specific Screening Tools
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HDAC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HDAC1 Recombinant Protein (WT & Y304F Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Folding). |
View HDAC1 Products |
| Gene Delivery | HDAC1 Lentivirus Particles Full-length ORF for nuclear localization studies. Titers >10^8 TU/ml. |
View HDAC1 Products |
| Benchmark Ab | Anti-HDAC1 Monoclonal (Catalytic Domain Epitope) Sequence-defined positive control for Western/IP applications. |
View HDAC1 Products |
| Validator | HDAC1 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View HDAC1 Products |
| Related Target: HDAC2 | HDAC2 Recombinant Protein Class I homology model for selectivity screening (86% identity). |
View HDAC2 Products |
| Related Target: HDAC6 | HDAC6 Recombinant Protein Class IIb counter-screening for tubulin deacetylase selectivity. |
View HDAC6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (Class I vs II) | HDAC1/2/3/6 Ortholog Panel (>95% purity, Sequence Verified by Mass Spec, Theoretical MW confirmed) |
| Drug Resistance Mechanisms | Catalytic Domain Mutants (Y304F) available for binding affinity studies (Sequence Verified) |
| Cellular Target Engagement | High-titer Lentivirus (>10^8 TU/ml) for stable HDAC1 overexpression lines (Endotoxin Controlled) |
| Specificity Controls | Validated siRNA and isoform-specific Antibodies included for assay de-risking |
Live HDAC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HDAC1 therapeutics is intensifying, with major players shifting focus from traditional pan-HDAC inhibitors to isoform-selective small molecules and PROTACs (target protein degraders). The therapeutic landscape is undergoing a strategic pivot from first-generation pan-HDAC inhibitors (e.g., Vorinostat, Panobinostat) toward selective Class I isoform targeting. As the catalytic core of the NuRD and Sin3 co-repressor complexes, HDAC1 represents a critical node in epigenetic regulation. The current R&D wave focuses on dissociating the anti-tumor efficacy from class IIb (HDAC6-related) toxicities, driving demand for isoform-selective chemical matter. Next-generation development emphasizes combination regimens with KRAS G12C inhibitors and immune checkpoint blockade, necessitating robust selectivity assays against the highly homologous HDAC2 and mechanistically distinct HDAC6.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors (HDAC1/2) | Regenacy, AstraZeneca, Roche, Karyopharm, Syndax | Oncology (AML, Solid Tumors, Lymphoma), Neurodegeneration (ALS) | Isoform Selectivity Panel (Need HDAC1 vs HDAC2 vs HDAC6 proteins with >95% purity) |
| PROTAC Degraders | Arvinas, C4 Therapeutics, Emerging Biotechs | Solid Tumors, Refractory Cancers | Ternary Complex Formation (Need HDAC1 + CRBN/VHL E3 ligase proteins; native conformation) |
| Combination Therapy (HDACi + KRASi) | Mirati, Various Academic | KRAS-mutant Lung/Colon | Synergistic Cellular Models (Need HDAC1 Lentivirus + KRAS Mutant Cell Lines) |
| Combination Therapy (Immune Checkpoint) | Merck, BMS | Immunotherapy Resistance | Cell-based PD markers (Need robust siRNA/Antibody tools) |
| Brain-Penetrant Inhibitors | Biogen, Academic Consortia | Alzheimer's, Huntington's Disease | CNS Penetration Assays (Need high-purity proteins for BBB permeability studies) |